These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 26417913)

  • 21. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY; Ho CH; Hsieh YH; Kikuchi T
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
    Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulatory, liver depot gene therapy for Pompe disease.
    Bond JE; Kishnani PS; Koeberl DD
    Cell Immunol; 2019 Aug; 342():103737. PubMed ID: 29295737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
    Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
    Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease.
    Han SO; Gheorghiu D; Chang A; Mapatano SH; Li S; Brooks E; Koeberl D
    Hum Gene Ther; 2022 May; 33(9-10):479-491. PubMed ID: 35081735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
    Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
    Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
    Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
    Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
    Cresawn KO; Fraites TJ; Wasserfall C; Atkinson M; Lewis M; Porvasnik S; Liu C; Mah C; Byrne BJ
    Hum Gene Ther; 2005 Jan; 16(1):68-80. PubMed ID: 15703490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.
    Elmallah MK; Falk DJ; Nayak S; Federico RA; Sandhu MS; Poirier A; Byrne BJ; Fuller DD
    Mol Ther; 2014 Apr; 22(4):702-12. PubMed ID: 24336173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
    Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
    Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
    Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
    McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
    Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's new and what's next for gene therapy in Pompe disease?
    Roger AL; Sethi R; Huston ML; Scarrow E; Bao-Dai J; Lai E; Biswas DD; El Haddad L; Strickland LM; Kishnani PS; ElMallah MK
    Expert Opin Biol Ther; 2022 Sep; 22(9):1117-1135. PubMed ID: 35428407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.
    Han SO; Li S; Everitt JI; Koeberl DD
    Hum Gene Ther; 2019 Jul; 30(7):855-864. PubMed ID: 30803275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.